Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CareDx ( (CDNA) ) has provided an announcement.
CareDx reported on February 24, 2026 that its board appointed Keith Kennedy as chief financial officer and chief operating officer effective February 26, 2026, also naming him principal financial and accounting officer. Kennedy, a seasoned finance and operations executive with prior leadership roles at PharmaLogic, Veracyte, MCG Capital and GE Capital, has served as CareDx’s COO since September 2024, and his expanded remit consolidates financial and operational oversight following the planned CFO transition.
The company also disclosed that Nathan Smith resigned as chief financial officer for personal reasons effective at the close of business on February 25, 2026, noting his departure was not tied to any dispute over financial reporting. Smith will receive a separation package including a cash payment equal to nine months of base salary, his 2025 bonus, limited COBRA premium reimbursement and partial vesting of restricted stock units, indicating an orderly leadership change aimed at minimizing disruption for investors and employees.
In a separate February 24, 2026 announcement, CareDx reported fourth‑quarter 2025 revenue of $108 million, up 25% year over year, with testing services, patient and digital solutions and product revenue all posting double‑digit growth. Despite a GAAP net loss of $4 million in the quarter and $21 million for the year, the company generated $7 million of adjusted EBITDA in the quarter, $32 million for 2025 and positive operating cash flow, reflecting underlying profitability once prior‑year litigation reversals and non‑cash items are excluded.
For full‑year 2025, revenue rose 14% to $380 million, driven by testing services revenue of $275 million and strong gains in patient, digital and product lines, while non‑GAAP net income reached $32 million and cash, cash equivalents and marketable securities stood at about $201 million after $88 million of share repurchases. Management highlighted steady demand across its transplant testing and digital platforms, pointing to both operational discipline and balance‑sheet strength as the group continues to invest in new diagnostics and workflow integrations.
CareDx also unveiled recent business developments including publication of new clinical data supporting its HeartCare offering, progress with Epic Aura integrations at transplant centers and the launch of the ImmuneScape multiomics platform through collaboration with 10x Genomics. The company further announced pivotal validation data for its AlloHeme test, marking a strategic expansion beyond solid‑organ transplantation into cell therapy and hematologic malignancies that could broaden its addressable market and reinforce its leadership in transplant and organ‑health diagnostics.
The company posted an updated corporate presentation dated February 24, 2026 on its website to reflect its latest financial and operational status. Together with the leadership transition and detailed financial results, these updates underscore CareDx’s effort to communicate its evolving strategy and performance to shareholders, clinicians and other stakeholders in a rapidly developing precision medicine landscape.
The most recent analyst rating on (CDNA) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on CareDx stock, see the CDNA Stock Forecast page.
Spark’s Take on CDNA Stock
According to Spark, TipRanks’ AI Analyst, CDNA is a Outperform.
CareDx’s strong financial performance and positive earnings call are the primary drivers of its stock score. The company’s robust revenue growth and improved profitability, along with strategic product launches and operational enhancements, contribute significantly to its favorable outlook. Technical indicators support a bullish trend, while the valuation remains reasonable. The absence of a dividend yield is a minor consideration.
To see Spark’s full report on CDNA stock, click here.
More about CareDx
CareDx, Inc., listed on Nasdaq as CDNA and branding itself as The Transplant Company, operates in precision medicine with a focus on improving outcomes for transplant patients and advancing organ health. The company offers integrated solutions including non‑invasive molecular tests for heart, kidney and lung transplantation, along with lab products, digital health technologies and patient services, positioning it as a leading provider of genomics‑based information for transplant care.
CareDx concentrates on clinically differentiated, high‑value healthcare tools for transplant patients and caregivers in the U.S. and abroad. Its portfolio spans testing services, patient and digital solutions and transplant‑related lab products, giving it a strong niche in the transplant diagnostics and organ‑health management market and underpinning its role in precision transplant medicine.
Average Trading Volume: 732,766
Technical Sentiment Signal: Hold
Current Market Cap: $1.03B
Find detailed analytics on CDNA stock on TipRanks’ Stock Analysis page.